Android app on Google Play

Unusual 11 Mid-Day Movers 01/04: (DRYS) (SCTY) (HNR) Higher; (ARAY) (SIMG) (FINL) Lower

January 4, 2013 12:55 PM EST Send to a Friend
Accuray Incorp. (Nasdaq: ARAY) 19.9% LOWER; announced preliminary results for the second quarter of fiscal 2013 that ended December 31, 2012 and updated guidance for fiscal 2013. Non-GAAP results are provided to enhance understanding of Accuray's ongoing core results of operations. For more color, click here.

DryShips (Nasdaq: DRYS) 17.9% HIGHER; moving higher on expectations of improved dry bulk prices in 2013. For more, click here.

SolarCity Corporation (Nasdaq: SCTY) 13.6% HIGHER; announced an update on the Company’s megawatts (MW) deployed for the Fiscal Year ended December 31, 2012 and Q4 2012, and provided guidance on this metric for 2013. Click here for the numbers.

Silicon Image (Nasdaq: SIMG) 12.7% LOWER; see fourth quarter revenue in the range of $59 million to $60 million. The Company's previous guidance for fourth quarter revenue was in the range of $64 million to $67 million. The reduction is the result of the rescheduling of certain orders by a large customer. The Street sees revs of $65.7 million.

Harvest Natural Resources, Inc. (NYSE: HNR) 12.3% HIGHER; announced that it has encountered oil in the wildcat well Dussafu Tortue Marin-1 (DTM-1) drilled in the Dussafu Marin PSC, in the offshore waters of Gabon, West Africa. Harvest operates the Dussafu PSC, holding a 66.667 percent interest.

Acme Packet (Nasdaq: APKT) 11.9% HIGHER; upgraded at Stifel Nicolaus to Buy with a $27 price target.

Amicus Therapeutics (Nasdaq: FOLD) 11.5% HIGHER; announced positive preliminary results from all 4 dose cohorts in a Phase 2 study (Study 010) to evaluate the safety and pharmacokinetic (PK) effects of the pharmacological chaperone AT2220 (duvoglustat HCl) co-administered with enzyme replacement therapy (ERT) for Pompe disease (Myozyme and Lumizyme).

Cytokinetics (Nasdaq: CYTK) 11.4% HIGHER; Initiated by Piper Jaffray at Overweight, with a price target of $4.

Corcept Therapeutics (Nasdaq: CORT) 11.1% HIGHER; Piper Jaffray started coverage with an Overweight rating and $4 price target.

Finish Line (Nasdaq: FINL) 6.4% LOWER; reported Q3 EPS of $0.00, $0.11 worse than the analyst estimate of $0.11. Revenue for the quarter came in at $296.6 million versus the consensus estimate of $298.48 million. Comps rose 3.6 percent. Sees Q4 2013 EPS of $0.74-$0.78, versus the consensus of $0.82. Also sees FY2013 EPS of $1.47-$1.51, versus the consensus of $1.64. The number is below prior expectations for 6 percent to 9 percent growth over $1.53 reported in FY12.

Support.com (Nasdaq: SPRT) 6.1% LOWER; B. Riley started coverage with a Neutral rating and $4.50 price target.

Discovery Laboratories, Inc. (Nasdaq: DSCO) 5.6% LOWER; announced changes to its board of directors and appointed a new Chief Executive Officer (CEO) in CFO John Cooper. For more on the change, click here.

To get this report daily visit http://www.streetinsider.com/entities/Unusual+11+Mid-Day+Movers.




You May Also Be Interested In


Related Categories

Special Reports

Related Entities

Piper Jaffray, Stifel Nicolaus, B. Riley, Unusual 11 Mid-Day Movers

Add Your Comment